PROFITS AND PLAGIARISM: THE CASE OF MEDICAL GHOSTWRITING
Article first published online: 16 FEB 2009
DOI: 10.1111/j.1467-8519.2008.00705.x
© 2009 The Author. Journal compilation © 2009 Blackwell Publishing Ltd.
Additional Information
How to Cite
ANEKWE, T. D. (2010), PROFITS AND PLAGIARISM: THE CASE OF MEDICAL GHOSTWRITING. Bioethics, 24: 267–272. doi: 10.1111/j.1467-8519.2008.00705.x
Publication History
- Issue published online: 9 JUN 2010
- Article first published online: 16 FEB 2009
Keywords:
- ghostwriting;
- honorary authors;
- medical ethics;
- pharmaceutical companies;
- plagiarism;
- public health;
- research misconduct
ABSTRACT
This paper focuses on medical ghostwriting in the United States. I argue that medical ghostwriting often involves plagiarism and, in those cases, can be treated as an act of research misconduct by both the federal government and research institutions. I also propose several anti-ghostwriting measures, including: 1) journals should implement guarantor policies so that researchers may be better held accountable for their work; 2) research institutions and the federal government should explicitly prohibit medical ghostwriting and outline appropriate penalties; and 3) a publicly available database should be created to record researchers' ethics violations.

1467-8519/asset/BIOE_left.gif?v=1&s=3b05bc86c343041a1446a18dd409e5a52324e3dc)
1467-8519/asset/BIOE_right.gif?v=1&s=0d433c41384786c9c12157a472a71b210cad5219)
